{"title":"冷冻处理对血液病患者脐血的影响","authors":"S. Pal, R. David","doi":"10.1115/imece2001/bed-23152","DOIUrl":null,"url":null,"abstract":"\n Cellular therapies promise to become major therapeutic modalities of this new century. The hematopoietic restoration with umbilical cord blood transplant can be a useful source of hematopoietic stem cells for routine bone marrow reconstitution. Thus it can be used as an effective source of stem cells for the treatment of various hematological disorders like leukemia, thalessaemia, aplastic anemia and it also can be used to replace the damaged tissue in various pathological conditions like Parkinson’s disease, Alzheimer’s, osteoarthritis etc. The advantage of the umbilical cord blood transplant being, use of unrelated umbilical cord blood transplantation with upto 2 to 3 HLA mismatch (Wagner et al, 1996).","PeriodicalId":7238,"journal":{"name":"Advances in Bioengineering","volume":"78 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2001-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Cryoprocessing on Umbilical Cord Blood for Hematological Disorders\",\"authors\":\"S. Pal, R. David\",\"doi\":\"10.1115/imece2001/bed-23152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n Cellular therapies promise to become major therapeutic modalities of this new century. The hematopoietic restoration with umbilical cord blood transplant can be a useful source of hematopoietic stem cells for routine bone marrow reconstitution. Thus it can be used as an effective source of stem cells for the treatment of various hematological disorders like leukemia, thalessaemia, aplastic anemia and it also can be used to replace the damaged tissue in various pathological conditions like Parkinson’s disease, Alzheimer’s, osteoarthritis etc. The advantage of the umbilical cord blood transplant being, use of unrelated umbilical cord blood transplantation with upto 2 to 3 HLA mismatch (Wagner et al, 1996).\",\"PeriodicalId\":7238,\"journal\":{\"name\":\"Advances in Bioengineering\",\"volume\":\"78 2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2001-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Bioengineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1115/imece2001/bed-23152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Bioengineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1115/imece2001/bed-23152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
细胞疗法有望成为新世纪的主要治疗方式。脐带血移植造血修复可作为常规骨髓重建的有效造血干细胞来源。因此,它可以作为干细胞的有效来源,用于治疗各种血液系统疾病,如白血病、地中海贫血、再生障碍性贫血,也可以用于替代各种病理条件下的受损组织,如帕金森病、阿尔茨海默病、骨关节炎等。脐带血移植的优点是,使用不相关的脐带血移植,最多有2到3个HLA不匹配(Wagner et al, 1996)。
Effect of Cryoprocessing on Umbilical Cord Blood for Hematological Disorders
Cellular therapies promise to become major therapeutic modalities of this new century. The hematopoietic restoration with umbilical cord blood transplant can be a useful source of hematopoietic stem cells for routine bone marrow reconstitution. Thus it can be used as an effective source of stem cells for the treatment of various hematological disorders like leukemia, thalessaemia, aplastic anemia and it also can be used to replace the damaged tissue in various pathological conditions like Parkinson’s disease, Alzheimer’s, osteoarthritis etc. The advantage of the umbilical cord blood transplant being, use of unrelated umbilical cord blood transplantation with upto 2 to 3 HLA mismatch (Wagner et al, 1996).